Clinical Trial Update: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor [Phase 3]

View source ↗

Summary

Riociguat was studied in a Phase 3 clinical trial for patients with pulmonary hypertension who had insufficient response to PDE-5 inhibitors. The study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Riociguat (Adempas) (riociguat)

Snippet

Sponsor: Bayer | Conditions: Hypertension, Pulmonary | Phase 3 | Status: COMPLETED